AHA 2025 | OPTIMA-AF: 1 Month vs. 12 Months of Dual Therapy (DOAC + P2Y12) After PCI in Atrial Fibrillation

Concomitant atrial fibrillation (AF) and coronary artery disease is a common occurrence in clinical practice. In these patients, current guidelines recommend 1 month of triple therapy (direct oral anticoagulation [DOAC] + dual antiplatelet therapy [DAPT]) followed by 12 months of dual therapy (DOAC + P2Y12 inhibitor) after percutaneous coronary intervention (PCI). The OPTIMA-AF study assessed whether a shorter regimen — 1 month of DOAC + P2Y12, followed by DOAC monotherapy — could maintain efficacy while reducing the bleeding risk.

This randomized trial, conducted in 75 centers in Japan, included 1088 patients with AF undergoing PCI. The primary endpoint (PEP) was a composite of death, myocardial infarction (MI), or stroke at 1 year. The safety endpoint was the incidence of bleeding or deterioration in quality of life over the same period.

All procedures used Xience stents and intravascular imaging (intravascular ultrasound [IVUS]/optical coherence tomography [OCT]) guidance. Patients received aspirin (ASA) + P2Y12 + DOAC during the periprocedural period. The design included analyses for noninferiority and superiority. Mean age was 75 years, 80% of subjects were men, 94.1% had chronic coronary syndromes, and clopidogrel was used as the P2Y12 inhibitor in 48.5% of cases.

Read also: AHA 2025 | CLOSURE-AF: Left Atrial Appendage Occlusion (LAAO) vs. Medical Therapy in Atrial Fibrillation with High Stroke and Bleeding Risk

In the PEP analysis, there was an absolute event difference of 0.9%, thus meeting the noninferiority criterion (4.5% [1 month] vs. 5.4% [12 months]; hazard ratio [HR] 1.20; 95% confidence interval [CI] 0.70–2.07; p=0.002). Regarding safety, the 1-month arm showed a significant reduction in clinically relevant bleeding (4.8% vs. 9.5%; HR 0.50; 95% CI 0.31–0.80; p=0.004), being superior in this aspect.

Conclusions

In AF patients undergoing PCI, a 1-month regimen of DOAC + P2Y12 inhibitor followed by DOAC monotherapy proved noninferior for ischemic events and halved the incidence of clinically relevant bleeding.

Presented by Yohei Sotomi during the Late-Breaking Science session at AHA 2025, New Orleans, USA.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Omar Tupayachi
Dr. Omar Tupayachi
Member of the Editorial Board of solaci.org

More articles by this author

EuroPCR 2026 | P2Y12 Inhibitor Monotherapy After Complex PCI in ACS: Results From the NEO-MINDSET COMPLEX Subanalysis

This is a summary of the NEO-MINDSET COMPLEX subanalysis, presented by Dr. Guy Prado at EuroPCR 2026, which evaluated P2Y12 inhibitor monotherapy versus dual...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

EuroPCR 2026 | Could clopidogrel replace aspirin as monotherapy after PCI?

This presentation, delivered during EuroPCR 2026, analyzed the clinical outcomes of clopidogrel monotherapy versus aspirin in patients who remained event-free for 12 months after...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

T-TEER: Beyond Traditional Pulmonary Hypertension Thresholds

Significant tricuspid regurgitation (TR) is associated with progressive functional deterioration, heart failure (HF) hospitalizations, and increased mortality. In recent years, transcatheter tricuspid edge-to-edge repair...

Is left atrial appendage closure safe in patients with reduced ejection fraction?

Patients with heart failure with reduced ejection fraction (HFrEF) were excluded from the major randomized trials evaluating percutaneous left atrial appendage closure (LAAC), and...

Left Atrial Appendage Closure in Spain: Sustained Growth and Favorable Real-World Outcomes

Oral anticoagulation remains the standard treatment for stroke prevention in patients with atrial fibrillation. However, many patients have a high bleeding risk or contraindications...